Amgen Inc. Stock Price Targets
Amgen Inc. (AMGN) Stock Price Targets & Analysis
Comprehensive analysis of short, mid, and long-term price targets for Amgen Inc. (AMGN).
Give me a comprehensive price target analysis for Amgen Inc. (AMGN).
Price Level Lines Drawn
- Low Target ($185.00): Red horizontal line
- Median Target ($312.00): Orange horizontal line
- High Target ($405.00): Green horizontal line
All lines extend 30 days into the future from today's date, providing clear visual support/resistance levels aligned with analyst expectations.
Comprehensive Price Target Analysis for AMGEN Inc. (AMGN)
Executive Summary
AMGN exhibits a robust valuation with solid fundamentals, yet its current stock price of ~$296.47 puts it near the median analyst target. While short-term catalysts could drive volatility, the mid and long-term outlook remains bullish based on growth and innovation trajectory. The stock's current technical indicators suggest a consolidation phase around support and resistance levels, with upward momentum building.
Fundamental Analysis
| Metric | Value | Commentary |
|---|---|---|
| Market Cap | $159.6B | Large-cap stability |
| P/E (Trailing) | 24.22 | Reasonable for biotech/Pharma |
| Forward P/E | 14.34 | Represents growth expectations |
| Price to Book | 21.48 | Premium valuation, indicating strong growth prospects |
| Return on Equity | 99.14% | Very high, indicating efficient capital use |
| Debt/Equity | 756.65 | High leverage, attention needed on debt management |
| Dividend Yield | 3.21% | Attractive income component |
Financial Health: Despite high debt levels, AMGN maintains strong profitability margins (gross 69.36%, operating 32.73%) and cash reserves (~$8B).
Earnings Analysis
Recent Earnings Performance
- EBITDA shows volatility, peaking in June 2025 at $4.08B.
- Net Income from continuing operations in Q2 2025: $1.43B, aligned with EPS (~$2.65).
EPS Trends
- Slight decline in current EPS (Q2 2025: $2.65) from previous quarters but overall stable growth YoY (~$21.06 in 2024 to $21.65 projected for 2025).
EPS Revisions
- Recent positive revisions (+12 last year, mainly 0-7 days) underscore ongoing analyst confidence.
- Slight downward revisions in the past week reflect caution but overall a stable sentiment.
Earnings Quality
- Revenue growth and margins suggest sustainability; R&D investments support future pipeline opportunities.
Technical Analysis
| Indicator | Insight |
|---|---|
| Price Action | Current price near resistance (~$297) |
| 50-Day MA | Affirmed support at ~$290; trending upward |
| RSI (14) | In mid-40s to 50s; no overbought/oversold signals |
| MACD | Bullish crossover in recent weeks, indicating momentum |
| Support/Resistance | Confirmed at ~$290 (support) and ~$300 (resistance until breakout) |
Analyst Consensus & Price Targets
| Target | Value | Number of Opinions |
|---|---|---|
| Median | $312 | 26 analysts |
| Mean | $311.54 | 26 analysts |
| High | $405 | - |
| Low | $185 | - |
The consensus aligns closely with the median target (~$312), indicating a moderate upward bias.
Price Target Analysis
- Short-Term (3 months): Near current levels, with catalysts like pipeline updates possibly pushing towards $310 resistance.
- Mid-Term (12 months): Target of $312 based on analyst consensus, supported by earnings growth, R&D pipeline, and potential macro tailwinds.
- Long-Term (3+ years): Potential for growth beyond $405 with continued innovation, approval of new therapies, and expanding market share.
Key Risks & Opportunities
Risks:
- High debt levels could pressure margins if revenue growth stalls.
- Regulatory hurdles and pipeline failures.
- Market volatility affecting biotech valuations.
Opportunities:
- Robust R&D pipeline with potential blockbusters.
- Increasing demand for biotech solutions.
- Dividends and consistent cash flow providing income attraction.
Investment Recommendation
Hold — with a medium-term target of approximately $312, promising upside, but watch for debt management and pipeline execution risks. The stock may offer a 5-10% return annually over 12-24 months, with longer-term upside possible if new therapies succeed.
Let me know if you'd like me to analyze further aspects or update with new market data!